Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.54 |
| ▸ | AR | P10275 | 6/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479391 | 1.00 | PGR (0.68) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918130 | 0.91 | PGR (0.79) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL15354859 | 0.91 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918127 | 0.91 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL2168575 | 0.91 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL2168200 | 0.91 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL12473404 | 0.91 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918110 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL544872 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL16016504 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348031-B9 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2348031-B1 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2348030-B1 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569276-B2 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2348031-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348030-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2033965-A2 | 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1242444-B1 | PROCESS FOR PREPARING 17ALPHA-ACETOXY-11BETA- 4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS, AND PROCESSES FOR PREPARING SUCH INTERMEDIATES | US GOV HEALTH & HUMAN SERV (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2005-06-30 | — | — | US | disclosed |
| US-6900193-B1 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-31 | — | — | US | disclosed |
| US-6768014-B2 | SELECTIVELY OXIDIZING 20-HYDROXYL GROUP OF 17 ALPHA, 20-DIHYDROXY-11 BETA -(4-(N,N-DIMETHYLAMINO)PHENYL)-21-METHOXY-19-NORPREGNA-4,9-DIE N-3-ONE WITH ORTHO-IODOXYBENZOIC ACID | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-07-27 | — | — | US | disclosed |
| US-20030060646-A1 | Process for preparing17alpha-acetoxy-11beta-[4-n,n(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene -3,20-dione, intermediates useful in the process , and processes for preparing such intermediates | NATIONAL INSTITUTES OF HEALTH | 2003-03-27 | — | — | US | disclosed |
| EP-1265911-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1242444-A1 | PROCESS FOR PREPARING 17ALPHA-ACETOXY-11BETA- 4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS, AND PROCESSES FOR PREPARING SUCH INTERMEDIATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001047945-A1 | PROCESS FOR PREPARING 17ALPHA-ACETOXY-11BETA-[4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS, AND PROCESSES FOR PREPARING SUCH INTERMEDIATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | CYP19A1, HSD17B11, CYP17A1 | PGR 4/4885NR3C1 61/4885AR 225/4885 |
| US-20030060646-A1 | Process for preparing17alpha-acetoxy-11beta-[4-n,n(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene -3,20-dione, intermediates useful in the process , and processes for preparing such intermediates | HSD17B11, CYP17A1, CYP19A1 | PGR 45/4885NR3C1 78/4885AR 156/4885 |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | HSD17B11, NR5A1, CYP19A1 | PGR 5/4885NR3C1 27/4885AR 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.